ADBIOTECH Decides to Issue 7.36 Million New Shares at 1,824 Won (30% Discount), Diluting Existing Shareholders by 37%
ADBIOTECH decided to conduct a third-party allotment of 7,358,388 new shares (37.4% of current outstanding) at 1,824 won per share, a 30% discount to the current market price of 2,625 won, to raise operating funds.
The entire proceeds of approximately 13.4 billion won will be used for labor costs and other operating expenses, not for productive investments or growth, limiting the potential for shareholder value enhancement.
This issuance will increase total shares outstanding to about 27 million, diluting existing shareholders by 37%. Although the major shareholder (BK Partners Investment Union 1) participates, the deep discount still harms minority shareholders.
The capital increase has been revised six times since the initial decision in October 2025, indicating uncertainty. Additionally, one of the allottees, E-Tron, received a disclaimer of opinion on its audit report, signaling financial risk.
[AI Comprehensive Analysis]This capital increase is extremely detrimental to existing shareholders due to massive dilution, deep discount, and use of funds for operating expenses. Short-term downward pressure on the stock price is expected, and confidence in management's capital-raising strategy may erode.
KOSDAQ Filing Information
Filing: [Correction of Description] Report on Major Events (Decision on Paid-in Capital Increase)